- Sales increased 6% and core sales increased 1% in Q3 2025.
- Net income rose 28% to $128 million, EPS up 30% to $1.92.
- Adjusted EBITDA grew 7% to $223 million, margin at 23.2%.
- $70 million returned to shareholders via repurchases and dividends.
Financial Performance
AptarGroup reported a 6% increase in sales and a 1% rise in core sales for Q3 2025. Net income grew by 28% to $128 million, with earnings per share (EPS) increasing by 30% to $1.92. Adjusted EPS, excluding non-ordinary-course litigation costs, rose 4% to $1.62.
Operational Highlights
The company experienced strong product volume growth in its Closures and Pharma segments, particularly in injectables. Adjusted EBITDA increased by 7% to $223 million, with an adjusted EBITDA margin of 23.2%, up from 22.9% in the previous year.
Shareholder Returns
Aptar returned $70 million to shareholders through share repurchases and dividends during the quarter.
Year-to-Date Performance
For the first nine months of 2025, reported sales increased by 3% and core sales by 1%. Net income rose 16% to $318 million, with EPS up 17% to $4.75. Adjusted EBITDA for the period increased by 8% to $624 million, with a margin of 22.2% compared to 21.2% in the prior year. The company returned $279 million to shareholders through share repurchases and dividends.
